All News

undifferentiated,arthritis,early,RA

Undiagnosed RA During the Pandemic

d EurekAlert!

The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.

Read Article
Target,T2T,bullseye

SLE T2T - Lupus Low Disease Activity State Predicts Outcomes

d Jack Cush, MD

Treat-to-target management of SLE has been shown to protect against organ damage and to improve quality of life. Now a prospective study shows that T2T with a goal of lupus low disease activity state and remission has been shown to improve mortality risk.

Read Article
addiction-71538__180.jpg

2022 CDC Clinical Practice Guideline on Opioid Prescribing

d CDC

The CDC has updated its Guideline for Prescribing Opioids for Chronic Pain and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1–3 months), and chronic (duration of >3 months) pain.

Read Article
DLE discoid lupus

ACR Promotes CME on Lupus Clinical Trials Racial Disparities

d ACR

The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their respective treatment areas and the importance of getting more of their African American/Black p

Read Article
change-948024_640.jpg

Can You Withdraw Ixekizumab in Stable Axial Spondyloarthritis?

d Jack Cush, MD

Remission often invites consideration of drug withdrawal in patients with axial spondyloarthritis (axSpA).

Read Article
woman,doctor

Lack of Gender Equity in Academic Rheumatology

d Jack Cush, MD

Evidence on gender equity in academic rheumatology in Europe is currently limited. This knowledge gap has a direct effect on the ability of professional bodies to improve gender equity. To address this, EULAR designed a study using web-based surveys to collect information; here are the results.

Read Article
beer.jpg

Excessive Alcohol-Related Deaths in US Adults

d Jack Cush, MD

Alcohol consumption is a leading preventable cause of death in the U.S.  A JAMA cross-sectional study suggests that between 2015 and 2019, an estimated 1 in 8 total deaths among U.S. adults ages 20 to 64 were attributable to excessive alcohol use, including 1 in 5 deaths among adults ages 20 to 49. 

Read Article
BIOBADASER registry study of 969 axSpA pts (315 females, 654 males; 2000-2019) who initiated a TNFi shows nonresponse (BASDAI50) was more likely in women (p=0.018), older age at the start of TNFi therapy. https://t.co/Zp7PWhEMav https://t.co/1XY0dC0QCW

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center study from UAB shows 72 gout pts treated & D/C from ED were Rx w/ steroids (64%), opioids (63%), NSAIDs (43%), colchicine (32%). But only 26/72 (36%) had subsequent outpatient clinic visit for gout. https://t.co/I8jjqIqJXd https://t.co/05YSibd6iz

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK inhibitor labeling in Canada updated to include risks of MACE, fatal VTE and cancer for tofacitinib (Xeljanz) (also applied to Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq Xeljanz) https://t.co/FEbHE4wN3I https://t.co/EN80i9cY5h

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Chao will be covering PsA and AS for the RheumNow team at #ACR22. “I’m looking forward to the exciting hybrid format of both in person and virtual meeting this year!” Follow @doctorRBC for real-time #ACR22 coverage. https://t.co/3sbBhVPPZ2
Dr. John Cush RheumNow ( View Tweet)
Introducing Dr. Akhil Sood, who will be covering #ACR22 on behalf of RheumNow. He is excited to learn more about the cutting-edge research in the field of Rheumatology & Immunology. Follow him @AkhilSoodMD for real-time coverage! https://t.co/hXw2CMrwKF
Dr. John Cush RheumNow ( View Tweet)
🆕Recommendation provided by Pharmacovigilance Risk Assessment Committee (#PRAC) about Janus kinase inhibitors #JAKi ⏩EMA recommends measures to minimise risk of serious side effects with #JAKi for chronic inflammatory disorders. https://t.co/YqaX7UxtUA https://t.co/dCJbqanAxF

Links:

Renaud Felten DocFelten ( View Tweet)
Think about checking Ig levels prior to Rituximab administration. Low IgM was most common after RTX in RA. The following are risk factors for hypogammaglobulinemia: 🧪 Older age 🧪 Use of steroids 🧪 Repeated doses of RTX 🧪 Low Ig at baseline https://t.co/oOjqnmFdYt
Catherine Sims, MD DrCassySims ( View Tweet)
RheumNow #ACR22 reporter, Dr. Bella Mehta, will be covering SLE, gout and auto inflammatory topics this year. “I am looking forward to meeting collegues at ACR after 2 years!” -Dr. Mehta Follow @bella_mehta for real-time coverage during #ACR22. https://t.co/QQM2NrObPR
Dr. John Cush RheumNow ( View Tweet)
Follow our newest #ACR22 reporter, Dr. Julian Segan ( @JulianSegan)! “I am looking forward to is meeting all my rheumatology Twitter heroes!” Follow @RheumNow and our reporters for real-time #ACR22 coverage. https://t.co/7axxfOV6W8
Dr. John Cush RheumNow ( View Tweet)
China study of 109 w/ MPO+ vasculitis (MPO-AAV), 23 w/ anti-GBM & 20 Double positive (MPO+ GBM+) (DPP) pts showed DPP pts were older(p=0.007), higher creatinine & lower GFR, & had multi-organ damage (cardiac) outside the kidney https://t.co/3aGPnfVDrs https://t.co/E557RLogCE

Links:

Dr. John Cush RheumNow ( View Tweet)
Drug-induced Hepatotoxicity - many Rheum drugs on the list: Tylenol, azathioprine, allopurinol, cyclosporine, dapsone, gold, MTX, 6-MP, NSAIDs, ASA, SSZ, Minocin... https://t.co/wuoVrDgesq https://t.co/SAWPdsQ6I3

Links:

Dr. John Cush RheumNow ( View Tweet)
What is RheumNow ACR reporter, Dr. Rachel Tate, most looking forward to at #ACR22? “Onsite, in person learning!” Follow @uptoTate for real-time #ACR22 coverage! https://t.co/nMw015dpdl
Dr. John Cush RheumNow ( View Tweet)
Opportunistic infections in #PsA pts on b/tsDMARDS is low. Metanalysis 47 studies, 17,197 pts - OI risk by MOA:1) JAK inhib 2.72%, 2) anti-IL-17 1.18%, 3) anti-IL-23 0.24% , 4) TNFi 0.01%. H. zoster w/ JAKi= 2.53% & Candida risk w/ IL-17=0.97% https://t.co/a5fJcWTxnL https://t.co/GQKoV7Hg6m

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×